Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) EPS (Weighted Average and Diluted) (2016 - 2025)

Palisade Bio has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at $1.08 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 256.52% to $1.08 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.35 through Dec 2025, up 96.79% year-over-year, with the annual reading at -$0.3 for FY2025, 97.06% up from the prior year.
  • EPS (Weighted Average and Diluted) was $1.08 for Q4 2025 at Palisade Bio, up from -$0.38 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.87 in Q4 2022 and troughed at -$12.96 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$3.55 (2023), against an average of -$3.51.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 1076.19% in 2022 and then skyrocketed 256.52% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.42 in 2021, then skyrocketed by 345.24% to $1.87 in 2022, then tumbled by 301.6% to -$3.77 in 2023, then surged by 81.7% to -$0.69 in 2024, then surged by 256.52% to $1.08 in 2025.
  • Per Business Quant, the three most recent readings for PALI's EPS (Weighted Average and Diluted) are $1.08 (Q4 2025), -$0.38 (Q3 2025), and -$0.58 (Q2 2025).